Adage Capital Partners Gp, L.L.C. Adds $95M in Axsome Therapeutics, Inc. ($AXSM)
Key Points
- Adage Capital Partners Gp, L.L.C. changed its Axsome Therapeutics, Inc. ($AXSM) stake by 100.7% last quarter, boosting to 737,578 shares worth $189.49 million.
- Wall Street's consensus rating on $AXSM is Strong Buy and an average price target of $275.28.
- $AXSM last traded around $256.91.
Adage Capital Partners Gp, L.L.C. increased its position in Axsome Therapeutics, Inc. ($AXSM) by 100.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 737,578 shares of Axsome Therapeutics, Inc. after buying 370,000 shares during the quarter. Adage Capital Partners Gp, L.L.C.'s holdings in Axsome Therapeutics, Inc. were worth $189.49 million as of its most recent filing.
Axsome Therapeutics, Inc. ($AXSM) Stock
Axsome Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.